Neurogenic Disorders of the Bladder in Parkinsonism1

Murnaghan, G. F.

doi:10.1111/j.1464-410x.1961.tb11636.x

Cited by 79 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cardiovascular symptoms were recorded in 79.8% of our patients, which is similar to the finding of Gallagher et al [60]. Urinary symptoms were recorded in 72.7% of our patients, which is within the range noted by other studies (38–71%) [60,63,64,65]. …”

Section: Discussionsupporting

confidence: 80%

Epidemiological Study and Clinical Profile of Parkinson’s Disease in the Assiut Governorate, Egypt: A Community-Based Study

Khedr

Attar²,

Kandil³

et al. 2012

Neuroepidemiology

View full text Add to dashboard Cite

Background: Few comprehensive epidemiological studies of the prevalence of Parkinson’s disease (PD) have been undertaken in Arab countries, and none has been carried out in Egypt. A community-based survey was conducted in the Assiut Governorate to estimate the prevalence and clinical profile of PD. Methods: A community-based study was carried out, with random sampling of 7 districts, involving 6,498 inhabitants. Out of this sample, 578 subjects dropped out, leaving 3,066 males (51.8%) and 2,854 females (48.2%). There were 3,660 urban residents (61.8%) and 2,260 (38.2%) from the rural community. Patients were evaluated using a screening questionnaire, the Unified Parkinson Disease Rating Scale and the Non-Motor Symptoms Scale for PD. Results: Thirty-nine subjects were found to have parkinsonism, giving a crude prevalence rate of 659/100,000 inhabitants. Of these subjects, 33 were diagnosed with PD (21 males), with a mean age of 66.9 ± 8.4 years, a crude prevalence rate of 557/100,000 and an age-specific prevalence rate (≥50 years old) of 2,748/100,000. There were more males than females (3,395 vs. 1,989/100,000), but the difference was not significant. The highest age-specific prevalence rate was recorded among subjects 70–79 years old (7,263/100,000). There was a significantly higher prevalence among rural than urban inhabitants (973 vs. 301/100,000) and among illiterate than literate persons (1,103 vs. 280/100,000). The clinical profile of our patients was similar to that of other populations but was characterized by a high prevalence of mood/cognition dysfunction and gastrointestinal symptoms; there were few reported perceptual problems. Conclusion: The overall prevalence of PD was high, especially in older adults.

show abstract

Section: Discussionsupporting

confidence: 80%

Epidemiological Study and Clinical Profile of Parkinson’s Disease in the Assiut Governorate, Egypt: A Community-Based Study

Khedr

Attar²,

Kandil³

et al. 2012

Neuroepidemiology

View full text Add to dashboard Cite

show abstract

“…The reported prevalence of LUT symptoms (LUTS) in patients with PD ranges from 38 to 71% 43–48. However, it has been difficult to determine to what extent PD contributes to LUTS.…”

Section: Bladder Dysfunction In Pdmentioning

confidence: 99%

Genitourinary dysfunction in Parkinson's disease

et al. 2010

View full text Add to dashboard Cite

Bladder dysfunction (urinary urgency/frequency) and sexual dysfunction (erectile dysfunction) are common nonmotor disorders in Parkinson's disease (PD). In contrast to motor disorders, genitourinary autonomic dysfunctions are often nonresponsive to levodopa treatment. The brain pathology causing the bladder dysfunction (appearance of overactivity) involves an altered dopamine-basal ganglia circuit, which normally suppresses the micturition reflex. By contrast, hypothalamic dysfunction is mostly responsible for the sexual dysfunction (decrease in libido and erection) in PD, via altered dopamine-oxytocin pathways, which normally promote libido and erection. The pathophysiology of the genitourinary dysfunction in PD differs from that in multiple system atrophy; therefore, it might aid in differential diagnosis. Anticholinergic agents are used to treat bladder dysfunction in PD, although these drugs should be used with caution particularly in elderly patients who have cognitive decline. Phosphodiesterase inhibitors are used to treat sexual dysfunction in PD. These treatments might be beneficial in maximizing the patients' quality of life.2010 Movement Disorder Society

show abstract

“…Seltener kommt es ausschließlich zu einer chronischen Restharnbildung bis hin zum Unvermögen, die Blase überhaupt entleeren zu können [1,2,3,4,5,6,7,8].…”

Section: Becken Können Ursachen Für Eine Nbfs Sein So Finden Sich Beunclassified

Diagnostik der neurogenen Blasenfunktionsstörung

Kaufmann

Kurze

2012

Urologe

View full text Add to dashboard Cite

Patients with congenital and acquired neurogenic bladder dysfunction due to central and peripheral nervous lesions are significantly limited in their daily lives. The neurogenic dysfunction of the bladder and lower urinary tract are often misinterpreted and later fed to a diagnosis. Without therapy severe complications, including renal damage, could be the consequence in the follow up. Therefore, dedicated diagnostics have to be done to recognize the different disorders and to determine the specific therapy. For these patients a lifelong bladder monitoring and neuro-urological management is necessary. This article describes techniques of neuro-urological testings and the interpretation in case of neurogenic disorders.

show abstract

Neurogenic Disorders of the Bladder in Parkinsonism1

Cited by 79 publications

References 7 publications

Epidemiological Study and Clinical Profile of Parkinson’s Disease in the Assiut Governorate, Egypt: A Community-Based Study

Epidemiological Study and Clinical Profile of Parkinson’s Disease in the Assiut Governorate, Egypt: A Community-Based Study

Genitourinary dysfunction in Parkinson's disease

Diagnostik der neurogenen Blasenfunktionsstörung

Contact Info

Product

Resources

About